Stay updated on Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial
Sign up to get notified when there's something new on the Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial page.

Latest updates to the Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial page
- Check5 days agoChange DetectedAn update to the page's revision tag from v3.5.4 to v3.5.5 was applied, indicating a backend/content-management update. This signals a page refresh or republishing rather than changes to the study data or listings.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check27 days agoChange DetectedPublications section updated: the older JCO reference with an Erratum is removed, and a newer JCO publication citation related to HER2-mutant cancers is added. This reflects an updated bibliographic record for results associated with the study.SummaryDifference0.1%

- Check48 days agoChange DetectedThe page revision indicator was updated from v3.5.2 to v3.5.3, reflecting an incremental site/version change without altering the displayed clinical trial study content.SummaryDifference0.1%

- Check55 days agoChange DetectedAdded an erratum note for the JCO 2018 publication. Updated the publication revision from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check84 days agoChange DetectedRevision: v3.5.0 was added. Revision: v3.4.3 was removed.SummaryDifference0.1%

- Check91 days agoChange DetectedThe page's revision label updated from v3.4.2 to v3.4.3. No trial content or visible details appear to be altered.SummaryDifference0.1%

Stay in the know with updates to Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ado-Trastuzumab Emtansine in HER2 Amplified Cancers Clinical Trial page.